Phase II Study of Glivec (Imatinib) in Locally Advanced and/or Metastatic Soft Tissue Sarcomas Expressing the t(17;22)(q22;q13) Translocation Resulting in a COL1A1/PDGF-beta Fusion Protein i.e. DermatoFibroSarcoma Protuberans (DFSP) and Giant Cell Fibroblastoma (GCF)
- Determine the therapeutic activity of imatinib mesylate in patients with locally
advanced or metastatic dermatofibrosarcoma protuberans or giant cell fibroblastoma.
- Determine the progression-free rate at 14 weeks in patients treated with this drug.
- Determine objective response rate, progression-free survival, and overall survival in
patients treated with this drug.
- Determine the duration of response in patients treated with this drug.
OUTLINE: This is an open-label, non-randomized, multicenter study.
Patients receive oral imatinib mesylate twice daily for at least 14 weeks in the absence of
disease progression or unacceptable toxicity. Patients with stable disease after 14 weeks
receive imatinib mesylate for 12 additional weeks. Patients with a partial or complete
response at 14 weeks undergo surgical resection if possible. If surgical resection of all
remaining tumor is not possible OR if complete resection is not achieved (section margins
positive), patients continue to receive imatinib mesylate in the absence of disease
Patients are followed monthly for 6 months, every 3 months for 6 months, every 6 months for
2 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 44 patients will be accrued for this study within 2 years.
Masking: Open Label, Primary Purpose: Treatment
Progression-free rate at 14 weeks
Allan T. van Oosterom, MD, PhD
United States: Federal Government